

# Activation of Peripheral $\kappa$ Opioid Receptors Inhibits Capsaicin-Induced Thermal Nociception in Rhesus Monkeys<sup>1</sup>

MEI-CHUAN KO, EDUARDO R. BUTELMAN,<sup>2</sup> and JAMES H. WOODS

Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, Michigan

Accepted for publication October 30, 1998 This paper is available online at <http://www.jpet.org>

## ABSTRACT

8-Methyl-*N*-vanillyl-6-nonenamide (capsaicin) was locally applied in the tail of rhesus monkeys to evoke a nociceptive response, thermal allodynia, which was manifested as reduced tail-withdrawal latencies in normally innocuous 46°C water. Coadministration of three  $\kappa$  opioid ligands, U50,488 (3.2–100  $\mu$ g), bremazocine (0.1–3.2  $\mu$ g), and dynorphin A(1–13) (3.2–100  $\mu$ g), with capsaicin in the tail dose-dependently inhibited capsaicin-induced allodynia. This local antinociception was antagonized by a small dose of an opioid antagonist, quadazocine; (0.32 mg), applied in the tail; however, this dose of quadazocine injected s.c. in the back did not antagonize local U50,488. Comparing the relative potency of either agonist or antagonist after local and systemic administration confirmed that the site

of action of locally applied  $\kappa$  opioid agonists is in the tail. In addition, local nor-binaltorphimine (0.32 mg) and oxilorphan (0.1–10  $\mu$ g) antagonist studies raised the possibility of  $\kappa$  opioid receptor subtypes in the periphery, which indicated that U50,488 produced local antinociception by acting on  $\kappa_1$  receptors, but bremazocine acted probably on non- $\kappa_1$  receptors. These results provide functional evidence that activation of peripheral  $\kappa$  opioid receptors can diminish capsaicin-induced allodynia in primates. This experimental pain model is a useful tool for evaluating peripherally antinociceptive actions of  $\kappa$  agonists without central side effects and suggests new approaches for opioid pain management.

There is a growing literature concerning the antinociceptive effectiveness of exogenous opioids administered in the periphery (for reviews, see Barber and Gottschlich, 1992; Stein 1995). In particular, locally administered opioid agonists produced antinociceptive effects by interacting with peripheral opioid receptors in inflamed tissues (e.g., Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996). Such receptors are present on peripheral sensory nerves where they can modulate both afferent and efferent neuronal functions to eventually result in antinociception (Carlton and Coggeshall, 1998). The discovery that modulation of nociceptive processes can occur in the periphery has stimulated research toward treatments that minimize central side effects. One possibility is the application of small, systemically inactive doses of analgesics directly into the injured tissue (Stein et al., 1991; Joshi et al., 1993). This may be useful, particularly under localized pathologic conditions. Another approach is the use of peripherally selective compounds,

which have a reduced ability to cross the blood-brain barrier (Junien and Riviere, 1995; Read et al., 1997). This provides the possibility of systemic administration and may be beneficial in painful conditions of a more dispersed origin. Many nociceptive conditions, including postoperative pain, cancer, and arthritis, are associated with inflammation. In establishing experimental pain models, it is valuable to explore potential antinociceptive agents and to investigate the mechanisms underlying various forms of inflammatory pain.

Capsaicin, the pungent ingredient in hot chili peppers, has been used to evoke nociceptive responses for evaluating antinociceptive agents in humans (Eisenach et al., 1997; Kinnman et al., 1997). Exposure of nociceptor terminals, such as C-fibers, to capsaicin initially leads to excitation of the neuron and, subsequently, to the painful perception and local release of inflammatory pain mediators such as Substance P and calcitonin gene-related peptide (CGRP; e.g., Holzer, 1991; Winter et al., 1995; Caterina et al., 1997). Capsaicin-sensitive nerve fibers play an important role in many types of nociceptive conditions, including arthritis and neuropathic pain (Barthó et al., 1990; Kim et al., 1995; Winter et al., 1995). It has been reported that topical or intradermal administration of capsaicin to human skin produces burning pain and allodynia/hyperalgesia responses (Simone et al.,

Received for publication August 31, 1998.

<sup>1</sup> Support for this research was provided by United States Public Health Services Grant DA00254. Preliminary results were presented at the 60<sup>th</sup> annual meeting of College on Problems of Drug Dependence, Scottsdale, AZ, June 13–18, 1998.

<sup>2</sup> Present address: Rockefeller University, New York, NY

**ABBREVIATIONS:** Capsaicin, 8-methyl-*N*-vanillyl-6-nonenamide; DYN A(1–13), dynorphin A(1–13); nor-BNI, nor-binaltorphimine; % MPE, percentage of maximum possible effect; CGRP, calcitonin gene-related peptide; U50,488, (trans)-3,4-dichloro-*N*-methyl-*N*[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide.

1989; LaMotte et al., 1992). Previously, we have characterized capsaicin-induced nociception in nonhuman primates (Ko et al., 1998b). After capsaicin was s.c. administered in the tail of rhesus monkeys, it dose-dependently produced thermal allodynia, which was manifested as reduced tail-withdrawal latencies in normally innocuous warm water. More interestingly, when small, systemically inactive doses of  $\mu$  opioid agonists were coadministered with capsaicin in the tail, they locally inhibited nociceptive responses. These findings support the feasibility of pharmacological studies of capsaicin-induced pain to investigate the function of peripheral opioid receptors (Eisenach et al., 1997; Kinnman et al., 1997).

$\kappa$  opioid agonists are of particular clinical interest because of their ability to modulate antinociceptive functions without  $\mu$  opioid-related side effects, which include constipation, pruritus, and respiratory depression. However, the centrally mediated effects of  $\kappa$  agonists, such as sedation and dysphoria, could also limit their usefulness (Pfeiffer et al., 1986; Walsh et al., 1998). Thus, it will be valuable to evaluate peripheral antinociception caused by  $\kappa$  agonists in different experimental pain models. To date, many studies indicate that activation of peripheral  $\kappa$  receptors contribute to relief of visceral pain (e.g., Junien and Riviere, 1995; Langlois et al., 1997; Burton and Gebhart, 1998). Although rodent studies have also investigated the functional ability of peripheral  $\kappa$  receptors against somatic pain (Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996), there are no primate studies exploring this possibility. Given the evidence that peripheral  $\kappa$  receptors may act on primary afferents to inhibit nociceptive transmission by C-fibers (Russell et al., 1987; Haley et al., 1990; Andreev et al., 1994), it is possible that activation of peripheral  $\kappa$  receptors may inhibit capsaicin-induced nociception in primates. In addition, the possibility of  $\kappa$  receptor subtypes has been raised. Based on pharmacological studies, antinociceptive effects of systemic  $\kappa$  agonists have been suggested to be mediated by  $\kappa$  receptor subtypes (e.g., Horan et al., 1991; Butelman et al., 1993, 1998; Ko et al., 1998a). It is interesting to further explore whether these  $\kappa$  agonists produce local antinociceptive effects through different receptor subtypes in the periphery.

Therefore, the aim of this study was to evaluate the hypothesis that local administration of  $\kappa$  opioid agonists can diminish capsaicin-induced nociception in rhesus monkeys. The antinociceptive effects of three  $\kappa$  ligands, U50,488, bremazocine, and dynorphin A(1–13) [DYN A(1–13)], were compared after local and systemic administration. In addition, further antagonism studies were performed to investigate the possible role of peripheral  $\kappa$  receptor subtypes in this procedure.

## Materials and Methods

**Subjects.** Six male and female adult rhesus monkeys (*Macaca mulatta*) with body weights ranging between 7.6 and 11.9 kg (their mean weight during this study was 9.7 kg) were used. They were housed individually with free access to water and were fed approximately 25 to 30 biscuits (Purina Monkey Chow; Ralston Purina Co., St. Louis, MO) and fresh fruit daily. All monkeys had previous experience in the tail-withdrawal procedure and did not have exposure to capsaicin and opioids for 1 month before the present study. Animals used in this study were maintained in accordance with the University Committee on the Use and Care of Animals in the Uni-

versity of Michigan, and the Guide for the Care and Use of Laboratory Animals (7th ed) by the Institute of Laboratory Animal Resources (Nat'l Acad Press, Washington D.C., revised 1996).

**Procedure.** Thermal antinociception was measured by a warm-water tail-withdrawal procedure that has been described previously (Ko et al., 1998b). Briefly, the subjects were seated in restraint chairs and the lower part of the shaved tail (approximately 15 cm) was immersed into warm water maintained at temperatures of 42, 46, and 50°C. Tail-withdrawal latencies were recorded manually on a computerized timer. A maximum cutoff latency (20 s) was recorded if the subjects failed to remove their tails by this time. Each experimental session began with control determinations at each temperature. Subsequent tail-withdrawal latencies were determined at 5, 15, 30, 45, and 60 min after injection. The subjects were tested one to two times at three temperatures in a varying order, with approximately 1- to 2-min intervals between tests. In most cases, experimental sessions were conducted once per week, except in the time course study of nor-binaltorphimine (nor-BNI) antagonism. A single dosing procedure was used in all test sessions.

**Experimental Design.** Capsaicin was injected s.c. in the terminal 1 to 4 cm of the tail, in a constant 0.1-ml volume. In this procedure, the small amount of capsaicin dose-dependently produced transient allodynia (5–30 min; Ko et al., 1998b). Based on this former characterization, 0.1 mg of capsaicin was chosen as a standard noxious stimulus for the present studies in 46°C water.

**Antinociceptive Effects of  $\kappa$  Agonists.** U50,488 (3.2–100  $\mu$ g), bremazocine (0.1–3.2  $\mu$ g), or DYN A(1–13) (3.2–100  $\mu$ g) was coadministered with capsaicin in the tail to assess local antinociceptive effects in 46°C water. Maximally effective local doses of the three agonists were also administered either in the back against capsaicin or in the tail against 50°C water in the absence of capsaicin. In addition, systemic antinociceptive effects of U50,488 (0.032–0.32 mg/kg) and DYN A(1–13) (0.1–3.2 mg/kg) were studied by s.c. administration in the midscapular region of the back immediately after capsaicin injection. As described below (see *Data Analysis*), comparisons were drawn between potency (ED<sub>50</sub> values) of locally administered agents and potency of the same agent administered systemically based on the weight of each animal.

**Antagonism of  $\kappa$  Agonist-Induced Antinociception.** Given that onset and distribution factors may be minimized with local administration, opioid antagonists were coadministered with capsaicin and the  $\kappa$  agonists in the tail to investigate local antagonist effects. In addition, the highest effective doses of different antagonists were injected s.c. in the back to verify whether the antagonist effects were localized in the tail.

There were three substudies in this experiment. First, quadazocine (0.01–0.32 mg) was coadministered with capsaicin and U50,488 (100  $\mu$ g) in the tail to evaluate local antagonist potency. Then, quadazocine (0.032–1 mg/kg) was given s.c. in the back 30 min before local injection of capsaicin and U50,488, to determine systemic antagonist potencies. Thus, the relative potency of quadazocine was compared by its ID<sub>50</sub> values obtained following local and systemic routes.

Second, nor-BNI, a  $\kappa$  antagonist, was administered to determine whether it displayed differential antagonism against the local effects of U50,488 (100  $\mu$ g) and bremazocine (3.2  $\mu$ g) in the tail. The dose of nor-BNI (0.32 mg) was initially chosen based on an approximately 100-fold potency difference relative to systemically effective doses in antinociceptive studies in rhesus monkeys (e.g., Butelman et al., 1993). We previously found that systemically administered nor-BNI (3.2 mg/kg) produced inconsistent antinociceptive effects during the first hour after injection. In addition, nor-BNI does not have a clear  $\kappa$  selectivity during the first hour after injection (Endoh et al., 1992). To avoid the possible interference of early action of nor-BNI, we used a paradigm similar to one used in a previous study (Butelman et al., 1993). Thus, the data were obtained from separate experiments, in which nor-BNI was initially administered s.c. in the marked tail on day 0. After the nor-BNI injection, the tail-withdrawal responses

were measured for 1 h. Then, the local antinociceptive effect of U50,488 or bremazocine against capsaicin was determined 1, 3, 7, 14, and 21 days after local nor-BNI administration by injecting in the marked location. The interval between two experimental sessions was at least 2 weeks. Multiple doses of nor-BNI antagonist were not given because frequent capsaicin exposure in the first week after nor-BNI pretreatment might desensitize the subject's nociceptive responses (Holzer, 1991).

Finally, oxilorphan was chosen to further evaluate the possibility of  $\kappa$  receptor subtypes in the periphery. Based on *in vivo* pA<sub>2</sub> analysis, oxilorphan displayed a  $\kappa_1$  antagonist selectivity, approximately 7- to 10-fold, in antinociception (M.-C.K., M. D. Johnson, D. W. Tyson, J. R. Traynor and J.H.W., in preparation). Oxilorphan (0.1–10  $\mu$ g) was coadministered with capsaicin and U50,488 (100  $\mu$ g) or bremazocine (3.2  $\mu$ g) in the tail to determine local antagonist potency. The differential potency of oxilorphan was compared with that of quadazocine, based on their local ID<sub>50</sub> values.

There were two groups of subjects in this study. The first group ( $n = 3$ ) was used in all experimental sessions. The second group ( $n = 3$ ) was used to confirm selected experimental data from the first group; in particular, studies of the time course of local nor-BNI antagonism, locally and systemically effective doses of  $\kappa$  agonists against capsaicin, and locally effective doses of antagonists (e.g., quadazocine and oxilorphan) were replicated.


**Data Analysis.** The 15-min time point was used for analysis because this was the time of peak effects of both capsaicin and  $\kappa$  agonists (Ko et al., 1998b). Individual tail-withdrawal latencies were converted to percentage of maximum possible effect (% MPE) by the formula: % MPE = [(test latency – control latency)/(cutoff latency, 20 s – control latency)]  $\times$  100. Individual control latencies were averaged from two determinations after application of 0.1 mg of capsaicin in the tail in 46°C water. Mean ED<sub>50</sub> values were obtained after log transformation of individual ED<sub>50</sub> values, which were calculated by least-squares regression using the portion of the dose-effect curves spanning the 50% MPE, and 95% CL values were also determined. Mean ID<sub>50</sub> values of antagonists were determined in the same manner by defining the dose that inhibited the 50% MPE induced by local  $\kappa$  agonists. Comparison of relative potencies of each compound administered locally or systemically was performed by converting the mg/kg units to total mg units based on the individual monkey's body weight (i.e., 0.1 mg/kg corresponds to 1 mg, assuming an approximate monkey weight of 10 kg). A significant difference was defined as a lack of overlap in the 95% CL of ED<sub>50</sub> or ID<sub>50</sub> values. In addition, the dose-dependent effects were analyzed with one-way ANOVA followed by the Newman-Keuls test ( $p < .01$ ). In the nor-BNI antagonism study, a significant reduction in tail-withdrawal latency was also determined by the Newman-Keuls test ( $p < .01$ ).

**Drugs.** U50,488 (Upjohn Co., Kalamazoo, MI), bremazocine methanesulfonate (Sandoz, Basel, Switzerland), DYN A(1–13) (National Institute on Drug Abuse, Bethesda, MD), quadazocine methanesulfonate (Sanofi, Malvern, PA), nor-BNI (obtained from Dr. H. I. Mosberg, Dept. of Medicinal Chemistry, University of Michigan), and oxilorphan tartrate (Bristol Myers Co., Wallingford, CT) were dissolved in sterile water. For systemic administration, all compounds were administered s.c. in the back, at a volume of 0.1 ml/kg. Capsaicin (Sigma Chemical Co., St. Louis, Mo) was dissolved in a solution of Tween 80/ethanol/saline in a ratio of 1:1:8. For local coadministration, all compounds were mixed in capsaicin solution and injected in a 0.1-ml volume in the tail.

## Results

**Nociceptive Effects of Capsaicin.** Normally, the monkeys kept their tails in 42 and 46°C water until the cutoff time (20 s), which indicated that both temperatures were innocuous. In contrast, they would remove their tails from 50°C water rapidly, typically within 1 to 3 s. When 0.1 mg of


capsaicin was injected into the tail, it evoked a nociceptive response, thermal allodynia, which was shown as reduced tail-withdrawal latencies. In particular, from 5 min after injection, capsaicin caused rapid tail-withdrawal latencies of approximately 2 s in 46°C water and this effect lasted for 30 min (Ko et al., 1998b). In the current study, administration of capsaicin caused erythema (redness) at the site of injection in only one monkey. This erythema could not be observed in all subjects due to dark pigmentation of the tail. Thus, a nociceptive response (reduced tail-withdrawal latencies) was used to examine the local effects of  $\kappa$  opioids in this preparation.



**Fig. 1.** Local antinociceptive effects of U50,488 (top), bremazocine (middle), and DYN A(1–13) (bottom) administered in the tail (slashed columns) or in the back (solid columns) against 46°C water in the presence of capsaicin (0.1 mg) or 50°C water in the absence of capsaicin. Each value represents the mean  $\pm$  S.E.M. ( $n = 3$ –6). Asterisks represent a significant difference (\*\* $p < .01$ ; \* $p < .05$ ) from control. Abscissae, agonist doses in  $\mu$ g. Ordinates, percentage of maximum possible effect (% MPE). Each data point was obtained 15 min after injection. See *Materials and Methods* for other details.

**Antinociceptive Effects of  $\kappa$  Agonists.** Figure 1 compares the local antinociceptive effects of three  $\kappa$  agonists, U50,488, bremazocine, and DYN A(1–13). Coadministration of U50,488 (3.2–100  $\mu$ g) with capsaicin (0.1 mg) in the tail dose-dependently inhibited capsaicin-induced thermal allodynia in 46°C water (Fig. 1, top). However, when applied in the back, the high dose of U50,488 (100  $\mu$ g) was not effective against capsaicin and it was not locally effective against a noxious stimulus, 50°C water, in the absence of capsaicin. Although the 15-min time point was used to analyze the data, it was worth noting that this ineffectiveness was observed throughout 1 h in the test session. Local administration of bremazocine (0.1–3.2  $\mu$ g) and DYN A(1–13) (3.2–100  $\mu$ g) also dose-dependently inhibited capsaicin-induced allodynia (Fig. 1, middle and bottom). Similarly, the antinociceptive effect of bremazocine and DYN A(1–13) was not observed when the high dose of bremazocine (3.2  $\mu$ g) or DYN A(1–13) (100  $\mu$ g) was applied in the back or when injected into the tail in 50°C water in the absence of capsaicin. The order of local antinociceptive potency ( $ED_{50}$ ) was bremazocine (1.0  $\mu$ g) > U50,488 (26.2  $\mu$ g)  $\geq$  DYN A(1–13) (27.9  $\mu$ g). As noted, the locally effective doses of these three  $\kappa$  agonists did not cause any behavioral changes, such as sedation, after injection.

Figure 2 illustrates the systemic antinociceptive effects of U50,488 and DYN A(1–13). After s.c. administration in the back, U50,488 (0.032–0.32 mg/kg) dose-dependently inhibited capsaicin-induced allodynia. Comparing the potency of both administration routes, local injection of U50,488 was approximately 70-fold more potent than systemic injection (Table 1). In contrast, s.c. administration of DYN A(1–13)



**Fig. 2.** Systemic antinociceptive effects of U50,488 (top) and DYN A(1–13) (bottom) administered s.c. in the back against capsaicin in 46°C water. Other details are as in Fig. 1.

(0.1–3.2 mg/kg) did not inhibit capsaicin-induced allodynia. This ineffectiveness was observed through the whole test session (5–60 min). Given that the mean weight of the monkeys was 9.7 kg during this study, 3.2 mg/kg DYN A(1–13) approximately corresponded to a 31-mg total dose per monkey. Thus, the antinociceptive potency of local DYN A(1–13) ( $ED_{50}$  = 27.9  $\mu$ g) was at least 1000-fold higher than s.c. DYN A(1–13) (Table 1).

**Antagonism of  $\kappa$  Agonist-Induced Antinociception.** Local administration of quadazocine (0.01–0.32 mg) antagonized the local antinociceptive effects of U50,488 (100  $\mu$ g) against capsaicin in a dose-dependent manner ( $ID_{50}$ , 0.028 mg; 95% CL, 0.017–0.044 mg; Fig. 3, top). When the locally effective dose of quadazocine (0.32 mg) was applied in the back, it did not antagonize local U50,488. This locally effective dose of quadazocine also significantly antagonized local bremazocine (3.2  $\mu$ g) and DYN A(1–13) (100  $\mu$ g; data not shown). Although systemic administration of quadazocine (0.032–1 mg/kg) dose-dependently antagonized local U50,488 ( $ID_{50}$ , 0.27 mg/kg; 95% CL, 0.11–0.64 mg/kg; Fig. 3, bottom), the relative antagonist potency of quadazocine was approximately 100-fold higher after local versus systemic injections.

Figure 4 illustrates the time course of local antagonist effects of nor-BNI (0.32 mg) against U50,488 and bremazocine. After s.c. injection of nor-BNI in the tail, there were no reduced or elevated tail-withdrawal latencies in 46 and 50°C water, respectively (data not shown). nor-BNI also did not change the monkeys' pain threshold from 24 h and beyond. This local nor-BNI pretreatment produced a significant antagonism against local U50,488 and the antagonist effect was observed up to 1 week after administration. The effects of local U50,488 then returned to control levels by 2 weeks after nor-BNI administration. In contrast, there were no significant antagonist effects of nor-BNI against local bremazocine through all test days (i.e., days 1–21) after nor-BNI pretreatment. In the same pretreatment paradigm, after 0.32 mg of nor-BNI was administered s.c. in the back, it did not antagonize local U50,488 one day after pretreatment (data not shown). The following time course experiment was not continued because we did not want to expose the subjects to frequent capsaicin administration to avoid possible desensitization (Holzer, 1991; Winter et al., 1995).

When oxilorphan was coadministered with capsaicin and U50,488 or bremazocine in the tail, it dose-dependently antagonized local antinociception of both  $\kappa$  agonists (Fig. 5). However, oxilorphan displayed a different antagonist potency against U50,488 and bremazocine in that it was approximately 7-fold more potent in antagonizing local U50,488 than bremazocine (Table 2). Similar to nor-BNI, the high dose of oxilorphan (10  $\mu$ g) alone did not change the monkey's nociceptive responses in this procedure (data not shown). However, quadazocine (0.01–0.32 mg) was coadministered with capsaicin and bremazocine in the tail. It also dose-dependently antagonized local bremazocine, although there was no significant differentiation in the antagonist potency of local quadazocine against U50,488 and bremazocine (Table 2).

## Discussion

The present study illustrated that local administration of  $\kappa$  opioid agonists significantly diminished capsaicin-induced nociception in a dose-dependent manner. The antagonist


TABLE 1  
Comparison of potencies of  $\kappa$  opioid agonists after local and systemic administration

Agonists	ED <sub>50</sub> <sup>a</sup> (95% CL)		Relative Potencies <sup>b</sup>
	Local (mg): in the tail	Systemic (mg/kg): in the back	
U50,488	0.026 (0.014–0.049)	0.186 (0.100–0.350)	68.7
Dynorphin A(1–13)	0.028 (0.010–0.081)	NA <sup>c</sup>	>1000

<sup>a</sup> ED<sub>50</sub> values were the mean of individual values ( $n = 3-6$ ).

<sup>b</sup> Values were the mean of individual relative potencies, which were obtained by converting mg/kg to total mg unit based on each monkey's body weight.


<sup>c</sup> Inactive up to 3.2 mg/kg.



**Fig. 3.** Antagonist effects of quadaozocine administered locally in the tail and systemically in the back against local U50,488 in 46°C water in the presence of capsaicin. The label cap + U50 represents the effects of coadministration of 0.1 mg of capsaicin and 100  $\mu$ g of U50,488 in the tail. Other details are as in Fig. 1.

study confirmed that this local antinociception was in the tail and could be mediated by  $\kappa$  opioid receptor subtypes. These results support the hypothesis that activation of peripheral  $\kappa$  opioid receptors can relieve nociception caused by capsaicin, which is thought to be mediated by stimulating primary afferent C-fibers (Holzer, 1991; Winter et al., 1995; Caterina et al., 1997).


**Antinociceptive Effects of  $\kappa$  Agonists.** This is the first demonstration that local administration of selective  $\kappa$  agonists U50,488, bremazocine, and DYN A(1–13) can inhibit capsaicin-induced thermal allodynia in nonhuman primates. The locally effective doses of three  $\kappa$  agonists, when applied in the back, did not inhibit capsaicin-induced allodynia. This indicates that the site of  $\kappa$  agonist-induced antinociception against capsaicin may be located in the tail. In particular, comparing the antinociceptive potency of U50,488 and DYN A(1–13) after local and systemic administration, DYN A(1–



**Fig. 4.** Time course of antagonist effects of nor-BNI (0.32 mg) administered locally in the tail against local U50,488 (top) and bremazocine (bottom) in 46°C water in the presence of capsaicin. Asterisks represent a significant difference ( $p < .01$ ) from cap + U50. The label cap + brem represents the effects of coadministration of 0.1 mg of capsaicin and 3.2  $\mu$ g of bremazocine in the tail. Other details are as in Fig. 3.

13), a  $\kappa$  opioid peptide, displayed a large difference in relative potency. Coadministration of DYN A(1–13) with capsaicin in the tail was at least 1000-fold more potent than s.c. administration of DYN A(1–13) in the back. At a dose up to 3.2 mg/kg, DYN A(1–13) did not produce any overt behavioral changes. In contrast, although 0.32 mg/kg U50,488 produced antinociception, this systemic dose also induced a moderate sedation in monkeys (Dykstra et al., 1987; the present study). This observation strengthens the notion that peripheral antinociception can be achieved by local administration of compounds into the injured tissue without producing central side effects (Barber and Gottschlich, 1992; Stein 1995; Wilson et al., 1996).

When a noxious thermal stimulus, 50°C water, was assessed in the absence of capsaicin, local application of  $\kappa$  agonists did not produce antinociception. These observations were similar to findings in rodents, in which the antinociceptive potency of opioid agonists is enhanced on the peripheral



**Fig. 5.** Local antagonist effects of oxilorphan against local U50,488 (top) and bremazocine (bottom) in 46°C water in the presence of capsaicin. The labels cap + U50 and cap + brem represent the effects of coadministration of capsaicin (0.1 mg) with U50,488 (100  $\mu$ g) and bremazocine (3.2  $\mu$ g) in the tail, respectively. Other details are as in Fig. 1.

**TABLE 2**

Comparison of potencies of opioid antagonists administered locally in the tail against U50,488 and bremazocine

Antagonists ( $\mu$ g)	ID <sub>50</sub> <sup>a</sup> (95% CL)		Relative Potencies <sup>b</sup>
	versus U50,488	versus bremazocine	
Quadazocine	27.8 (17.4–44.4)	53.6 (13.2–218.1)	2.2
Oxilorphan	0.27 (0.12–0.59)	1.82 (0.88–3.87)	7.0*

<sup>a</sup> ID<sub>50</sub> values were the mean of individual values ( $n = 3$ ).

<sup>b</sup> Values were the mean of individual relative potencies, which were obtained by dividing the ID<sub>50</sub> value versus bremazocine by the ID<sub>50</sub> value versus U50,488.

\* Indicates that the ID<sub>50</sub> of oxilorphan antagonism of bremazocine is significantly different from that for U50,488.

terminals of nociceptive primary afferents innervating inflamed tissue (Stein et al., 1989; Andreev et al., 1994; Nagasaka et al., 1996). There are several factors that may account for the increased effectiveness of locally administered opioids in a variety of nociceptive origins. For instance, opioid agonists may have easier access to neuronal opioid receptors due to perineurial disruption (Antonijevic et al., 1995). The activity of peripheral sensory fibers is dynamically regulated by the products of tissue injury and inflammation, as well as by a number of exogenous irritant chemicals (Levine et al., 1993; Dray 1997; Carlton and Coggeshall, 1998). The observation that local administration of  $\kappa$  agonists is more effective in inflamed tissue could, therefore, have therapeutic value, considering that many painful conditions are associated with tissue injury and inflammation.

Capsaicin evokes pain sensations by activating C-fiber nociceptors and stimulating the release of neuropeptides such

as Substance P and CGRP from primary nociceptive afferents (Holzer 1991; Winter et al., 1995; Caterina et al., 1997; Kilo et al., 1997). Both Substance P and CGRP play an important role in neurogenic inflammation and contribute to the transmission of nociceptive information (McDonald et al., 1996; Kilo et al., 1997; Cao et al., 1998). It will be interesting to investigate whether Substance P or CGRP antagonists can relieve capsaicin-induced nociception in this procedure. In contrast, activation of peripheral  $\kappa$  receptors has been shown to inhibit the excitability of nociceptive neurons (Russell et al., 1987; Haley et al., 1990; Andreev et al., 1994) and to reduce the release of Substance P from peripheral sensory endings (Yonehara et al., 1992). In addition, *in vitro* evidence also supports the inhibitory effects of  $\kappa$  opioid receptors (e.g., Levine et al., 1993; Schafer et al., 1994; Minami et al., 1995). Capsaicin-sensitive nerve fibers are involved in a variety of nociceptive conditions (Barthó et al., 1990; Kim et al., 1995; Winter et al., 1995). Given the observation that activation of peripheral  $\kappa$  receptors can produce antinociception in different experimental pain models (Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996; the present study), clinical studies should explore the possibility of local administration of  $\kappa$  opioids for painful conditions with various inflammatory components.

#### Antagonism of $\kappa$ Agonist-Induced Antinociception.

Local administration of quadazocine, an opioid antagonist, dose-dependently antagonized the local inhibition of U50,488 against capsaicin-induced allodynia. However, the locally effective dose of quadazocine, when applied in the back, did not antagonize local U50,488. This observation confirms the local agonist study, indicating that the site of action of locally applied  $\kappa$  opioids is in the tail. Similarly, a greater relative potency of quadazocine after local versus systemic routes was observed. Compared with a previous study (Ko et al., 1998b), quadazocine is approximately 7-fold more potent in antagonizing fentanyl than U50,488. This different antagonist potency of quadazocine against  $\mu$  versus  $\kappa$  agonists is expected because quadazocine has a higher affinity for  $\mu$  receptors than  $\kappa$  receptors in binding preparations (Negus et al., 1993). Quadazocine has been used previously to differentiate  $\mu$  receptor- and  $\kappa$  receptor-mediated effects *in vivo* (e.g., Negus et al., 1993).

$\kappa$  selective actions of locally applied  $\kappa$  agonists were further investigated. The local nor-BNI antagonist study raised the possibility of  $\kappa$  receptor subtypes in the periphery. As previously demonstrated by nor-BNI and naltrexone antagonist studies, systemic U50,488 and bremazocine produced antinociception probably through  $\kappa_1$  and non- $\kappa_1$  receptors, respectively, in rhesus monkeys (Butelman et al., 1993, 1998; Ko et al., 1998a). In the present preparation, lack of antagonism by nor-BNI against local bremazocine is consistent with results of a previous study using systemic administration of nor-BNI in this species (Butelman et al., 1993). Local nor-BNI displayed a shorter duration of antagonism against local U50,488. This could be due to the site of action (i.e., central versus peripheral) or the smaller local dose that was applied. A larger dose of nor-BNI, applied locally in the tail, could therefore have a longer duration of antagonism against U50,488.

In addition to the nor-BNI antagonist study, oxilorphan was used to evaluate the possibility of  $\kappa_1$  opioid receptor subtypes. Similar to naltrexone *in vivo* pA<sub>2</sub> analysis (Ko et

al., 1998a), oxilorphan has a 7- to 10-fold selectivity for  $\kappa_1$  over non- $\kappa_1$  effects (Ko, 1998). In the present study, local administration of oxilorphan significantly differentiated U50,488- and bremazocine-induced antinociception. In contrast, local quadazocine displayed similar antagonist potency against both  $\kappa$  agonists. These results suggested that U50,488 produced local antinociception by acting on  $\kappa_1$  receptors, but bremazocine might produce local antinociception on non- $\kappa_1$  receptors. Although bremazocine displayed a high affinity for  $\mu$  receptor sites, it is unlikely that bremazocine produced antinociception mainly through  $\mu$  opioid receptors in rhesus monkeys. This can be explained by two functional observations. One is that systemic bremazocine-induced antinociception was not influenced by clocinnamox, a functionally irreversible  $\mu$  antagonist (Ko et al., 1998a). The other finding is that quadazocine displayed similar potency against U50,488 and bremazocine, but it was more potent in antagonizing  $\mu$  agonists, such as fentanyl and [D-Ala<sup>2</sup>,N-Me-Phe<sup>4</sup>,Gly-ol<sup>5</sup>]-enkephalin, in this procedure (Ko et al., 1998b). Furthermore, bremazocine has been characterized to be a  $\mu$  antagonist by *in vitro* preparations (e.g., Corbett and Kosterlitz, 1986).

Several studies in rodents have suggested that  $\kappa$  opioids ( $\kappa_1$  versus  $\kappa_2$ ) have distinctive cardiovascular and neurophysiological profiles (Herrero and Headley, 1993; Schoffelemeier et al., 1997). Also,  $\kappa_2$  receptors may represent an important route to the modulation of N-methyl-D-aspartate receptor function on certain neuropathologies (Caudle et al., 1994). Other studies have emphasized that  $\kappa$  agonists are promising analgesics for treating visceral pain because they are effective on irritable bowel syndrome mainly through peripheral actions, but  $\mu$  and  $\delta$  agonists have direct inhibitory effects on motility and transit, which makes their use deleterious (Junien and Riviere, 1995; Langlois et al., 1997; Read et al., 1997; Burton and Gebhart, 1998). The present study only suggests the functional possibility of  $\kappa$  receptor subtypes in the periphery against somatic pain. More studies would be needed to determine whether  $\kappa$  subtype agonists have different analgesic efficacy against a variety of pain modalities in primates. To date, due to lack of  $\kappa_2$  subtype-selective antagonists and lack of identification of separate clones, there have been difficulties in clarifying the exact nature of proposed  $\kappa$  receptor subtypes. The development of  $\kappa$  subtype-selective agonists and antagonists would facilitate the pharmacological characterization of these putative receptor subtypes and allow exploration of their potential therapeutic profiles.

In summary, this report demonstrates that local administration of  $\kappa$  opioid agonists diminishes capsaicin-induced thermal nociception in nonhuman primates. This experimental pain model could provide a useful tool for evaluating newly developed  $\kappa$  agonists and expand new approaches for opioid pain management, such as local administration of  $\kappa$  agonists or the use of peripherally selective  $\kappa$  agonists.

#### Acknowledgments

The authors express their gratitude to Beck McLaughlin for help in preparing the manuscript and Mark Johnson and John Bussenbark for technical assistance.

#### References

- Andreev N, Urban L and Dray A (1994) Opioids suppress spontaneous activity of polymodal nociceptors in rat paw skin induced by ultraviolet irradiation. *Neuroscience* **58**:793–798.
- Antonijevic I, Mousa SA, Schäfer M and Stein C (1995) Perineurial defect and peripheral opioid analgesia in inflammation. *J Neurosci* **15**:165–172.
- Barber A and Gottschlich R (1992) Opioid agonists and antagonists: An evaluation of their peripheral actions in inflammation. *Med Res Rev* **12**:525–562.
- Barthó L, Stein C and Herz A (1990) Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opioid antinociception in inflammation. *Naunyn-Schmiedeberg's Arch Pharmacol* **342**:666–670.
- Burton MB and Gebhart GF (1998) Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. *J Pharmacol Exp Ther* **285**:707–715.
- Butelman ER, Negus SS, Ai Y, de Costa BR and Woods JH (1993) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. *J Pharmacol Exp Ther* **267**:1269–1276.
- Butelman ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bommel B, Zernig G and Woods JH (1998) Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. *J Pharmacol Exp Ther* **285**:595–601.
- Cao YQ, Mantyh PW, Carlson EJ, Gillespie A-M, Epstein CJ and Basbaum AI (1998) Primary afferent tachykinins are required to experience moderate to intense pain. *Nature* **392**:390–394.
- Carlton SM and Coggeshall RE (1998) Nociceptive integration: Does it have a peripheral component? *Pain Forum* **7**:71–78.
- Caterina MJ, Schumacher MA, Tominaga M, Rosen T, Levine JD and Julius D (1997) The capsaicin receptor: A heat-activated ion channel in the pain pathway. *Nature (London)* **389**:816–824.
- Caudle RM, Chavkin C and Dubner R (1994) K<sub>2</sub> opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells. *J Neurosci* **14**:5580–5589.
- Corbett AD and Kosterlitz HW (1986) Bremazocine is an agonist at  $\kappa$ -opioid receptors and an antagonist at  $\mu$ -opioid receptors in the guinea-pig myenteric plexus. *Br J Pharmacol* **89**:245–249.
- Dray A (1997) Peripheral mediators of pain, in *The Pharmacology of Pain* (Dickenson A and Besson J-M eds) pp 21–41, Springer-Verlag, Berlin.
- Dykstra LA, Gmerek DE, Winger G and Woods JH (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. *J Pharmacol Exp Ther* **242**:413–420.
- Eisenach JC, Hood DD, Curry R and Tong C (1997) Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. *Anesthesiology* **86**:1279–1287.
- Endoh T, Matsuura H, Tanaka C and Nagase H (1992) Nor-binaltorphimine: A potent and selective  $\kappa$ -opioid receptor antagonist with long-lasting activity *in vivo*. *Arch Int Pharmacodyn* **316**:30–42.
- Haley J, Ketchum S and Dickenson A (1990) Peripheral  $\kappa$ -opioid modulation of the formalin response: An electrophysiological study in the rat. *Eur J Pharmacol* **191**:437–446.
- Herrero JF and Headley PM (1993) Functional evidence for multiple receptor activation by  $\kappa$ -ligands in the inhibition of spinal nociceptive reflexes in the rat. *Br J Pharmacol* **110**:303–309.
- Holzer P (1991) Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons. *Pharmacol Rev* **43**:143–201.
- Horan PJ, de Costa BR, Rice KC and Porreca F (1991) Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: Evidence of kappa opioid receptor multiplicity in mice. *J Pharmacol Exp Ther* **257**:1154–1161.
- Joshi GP, McCarroll SM, O'Brien TM and Lenane P (1993) Intraarticular analgesia following knee arthroscopy. *Anesth Analg* **76**:333–336.
- Junien J-L and Riviere P (1995) Review article: The hypersensitive gut - peripheral kappa agonists as a new pharmacological approach. *Aliment Pharmacol Ther* **9**:117–126.
- Kilo S, Harding-Rose C, Hargreaves KM and Flores CM (1997) Peripheral CGRP release as a marker for neurogenic inflammation: A model system for the study of neuropeptide secretion in rat paw skin. *Pain* **73**:201–207.
- Kim YI, Na HS, Han JS and Hong SK (1995) Critical role of the capsaicin-sensitive nerve fibers in the development of the causal symptoms produced by transecting some but not all of the nerves innervating the rat tail. *J Neurosci* **15**:4133–4139.
- Kinnman E, Nygård EB and Hansson P (1997) Peripherally administered morphine attenuates capsaicin-induced mechanical hypersensitivity in humans. *Anesth Analg* **84**:595–599.
- Ko MC (1998) Pharmacological assessment of thermal antinociception mediated by kappa opioid receptors in rhesus monkeys. (Doctoral Dissertation). The University of Michigan, Ann Arbor, 119 p.
- Ko MC, Butelman ER, Traynor JR and Woods JH (1998a) Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA<sub>2</sub> analysis in rhesus monkeys. *J Pharmacol Exp Ther* **285**:518–526.
- Ko MC, Butelman ER and Woods JH (1998b) The role of peripheral  $\mu$  opioid receptors in the modulation of capsaicin-induced thermal nociception in rhesus monkeys. *J Pharmacol Exp Ther* **286**:150–156.
- Langlois A, Diop L, Friese N, Pascaud X, Junien J-L, Dahl SG and Riviere PJM (1997) Fedotozine blocks hypersensitive visceral pain in conscious rats: Action at peripheral  $\kappa$ -opioid receptors. *Eur J Pharmacol* **324**:211–217.
- LaMotte RH, Lundberg LER and Torebjörk HE (1992) Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. *J Physiol* **448**:749–764.
- Levine JD, Fields HL and Basbaum AI (1993) Peptides and the primary afferent nociceptor. *J Neurosci* **13**:2273–2286.
- McDonald DM, Bowden JJ, Baluk P and Bunnett NW (1996) Neurogenic inflammation. A model for studying efferent actions of sensory nerves. *Adv Exp Med Biol* **410**:453–462.
- Minami M, Maekawa K, Yabuuchi K and Satoh M (1995) Double *in situ* hybridiza-

- tion study on coexistence of  $\mu$ -,  $\delta$ - and  $\kappa$ -opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. *Mol Brain Res* **30**:203–210.
- Nagasaka H, Awad H and Yaksh TL (1996) Peripheral and spinal actions of opioids in the blockade of the autonomic response evoked by compression of the inflamed knee joint. *Anesthesiology* **85**:808–816.
- Negus SS, Burke TF, Medzihradsky F and Woods JH (1993) Effects of opioid agonists selective for  $\mu$ -,  $\kappa$ -, and  $\delta$  opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. *J Pharmacol Exp Ther* **267**:896–903.
- Pfeiffer A, Brantl V, Herz A and Emrich HM (1986) Psychotomimesis mediated by  $\kappa$  opiate receptors. *Science (Wash DC)* **233**:774–776.
- Read NW, Abitbol JL, Bardhan KD, Whorwell PJ and Fraitag B (1997) Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. *Gut* **41**:664–668.
- Russell NJW, Schaible H-G and Schmidt RF (1987) Opiates inhibit the discharges of fine afferent units from inflamed knee joint of the cat. *Neurosci Lett* **76**:107–112.
- Schafer MK-H, Bette M, Romeo H, Schwaebel W and Weihe E (1994) Localization of  $\kappa$ -opioid receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord. *Neurosci Lett* **167**:137–140.
- Schoffelmeer ANM, Hogenboom F and Mulder AH (1997)  $\kappa_1$ - and  $\kappa_2$ -opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. *Br J Pharmacol* **122**:520–524.
- Simone DA, Baumann TK and LaMotte RH (1989) Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. *Pain* **38**:99–107.
- Stein C, Millan MJ, Shippenberg TS, Peter K and Herz A (1989) Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of  $\mu$ ,  $\delta$  and  $\kappa$  receptors. *J Pharmacol Exp Ther* **248**:1269–1275.
- Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A and Peter K (1991) Analgesic effect of intraarticular morphine after arthroscopic knee surgery. *N Engl J Med* **325**:1123–1126.
- Stein C (1995) The control of pain in peripheral tissue by opioids. *N Engl J Med* **332**:1685–1690.
- Walsh SL, Strain EC, Abreu ME and Bigelow GE (1998) Pharmacodynamic profile of enadoline, a selective kappa agonist, in humans. 60<sup>th</sup> Annual Meeting of College on Problems of Drug Dependence; June 13–18, 1998; Scottsdale, AZ.
- Wilson JL, Nayanar V and Walker JS (1996) The site of anti-arthritic action of the  $\kappa$ -opioid, U-50,488H, in adjuvant arthritis: Importance of local administration. *Br J Pharmacol* **118**:1754–1760.
- Winter J, Bevan S and Campbell EA (1995) Capsaicin and pain mechanisms. *Br J Anaesth* **75**:157–168.
- Yonehara N, Imai Y, Chen J-Q, Takiuchi S and Inoki R (1992) Influence of opioids on substance P release evoked by antidromic stimulation of primary afferent fibers in the hind instep of rats. *Regul Pept* **38**:13–22.

---

**Send reprint requests to:** Mei-Chuan Ko, Ph.D., Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109–0632. E-mail: mko@umich.edu

---